Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Becton Dickinson's Other Operating Expense for the
three
months ended in Mar. 2026 was MXN1,190 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was MXN8,034 Mil.
Becton Dickinson's quarterly Other Operating Expense
declined
from Sep. 2025 (MXN5,228 Mil) to Dec. 2025 (MXN900 Mil) but then
increased
from Dec. 2025 (MXN900 Mil) to Mar. 2026 (MXN1,190 Mil).
Becton Dickinson's annual Other Operating Expense
increased
from Sep. 2023 (MXN-3,658 Mil) to Sep. 2024 (MXN4,371 Mil) and
increased
from Sep. 2024 (MXN4,371 Mil) to Sep. 2025 (MXN7,264 Mil).
Becton Dickinson Other Operating Expense Related Terms
Becton Dickinson Other Operating Expense Historical Data
* Premium members only.
The historical data trend for Becton Dickinson's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN8,034 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of MXN8,034 Mil mean?
Becton Dickinson (MEX:BDX) has a Other Operating Expense of MXN8,034 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on Becton Dickinson and its competitors.
Is Becton Dickinson's Other Operating Expense too high?
Becton Dickinson's current Other Operating Expense is MXN8,034 Mil. Overall, Becton Dickinson has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Becton Dickinson's Other Operating Expense compare to MDLN and RMD?
Becton Dickinson's Other Operating Expense of MXN8,034 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Medical Devices & Instruments company?
A good Other Operating Expense depends on the Medical Devices & Instruments industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Becton Dickinson and its competitors. Becton Dickinson's current Other Operating Expense is MXN8,034 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Becton Dickinson stock overvalued right now?
Based on GuruFocus' analysis, Becton Dickinson (MEX:BDX) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN3,256.78, compared to a current price of MXN2,683.83 — trading 17.6% below its estimated fair value. The current Other Operating Expense is MXN8,034 Mil. Becton Dickinson's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Becton Dickinson (MEX:BDX), the current Other Operating Expense is MXN8,034 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Becton Dickinson (MEX:BDX) Overvalued in 2026?
Based on GuruFocus' analysis, Becton Dickinson stock appears to be undervalued.
The current stock price of MXN2,683.83 is trading 17.6% below its estimated GF Value™ of MXN3,256.78.
GuruFocus considers Becton Dickinson to be Modestly Undervalued.
Key valuation signals for MEX:BDX:
Other Operating Expense: MXN8,034 Mil
GF Value™: MXN3,256.78 vs. price of MXN2,683.83 (17.6% below fair value)
No single metric tells the full story. See the MEX:BDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
74GF Score
Get the complete analysis for MEX:BDX
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BDX has been successfully added to your 
